Your browser is no longer supported. Please, upgrade your browser.
Settings
BNTX BioNTech SE daily Stock Chart
BNTX [NASD]
BioNTech SE
Index- P/E- EPS (ttm)-0.58 Insider Own1.26% Shs Outstand213.17M Perf Week18.73%
Market Cap16.58B Forward P/E147.03 EPS next Y0.53 Insider Trans0.00% Shs Float50.34M Perf Month60.04%
Income-130.30M PEG- EPS next Q-0.23 Inst Own3.30% Short Float6.51% Perf Quarter86.48%
Sales153.60M P/S107.95 EPS this Y-300.50% Inst Trans0.70% Short Ratio1.67 Perf Half Y96.02%
Book/sh- P/B- EPS next Y158.00% ROA- Target Price42.78 Perf Year-
Cash/sh2.52 P/C30.90 EPS next 5Y- ROE- 52W Range12.52 - 105.00 Perf YTD129.57%
Dividend- P/FCF- EPS past 5Y- ROI-31.40% 52W High-25.92% Beta-
Dividend %- Quick Ratio3.70 Sales past 5Y- Gross Margin88.30% 52W Low521.00% ATR5.55
Employees1179 Current Ratio3.70 Sales Q/Q5.80% Oper. Margin- RSI (14)73.93 Volatility7.74% 8.66%
OptionableYes Debt/Eq0.21 EPS Q/Q- Profit Margin- Rel Volume4.61 Prev Close77.78
ShortableYes LT Debt/Eq0.16 EarningsMay 12 BMO Payout- Avg Volume1.97M Price77.78
Recom2.60 SMA2027.85% SMA5043.63% SMA200100.25% Volume0 Change0.00%
Jun-30-20Downgrade H.C. Wainwright Buy → Neutral
May-19-20Upgrade H.C. Wainwright Neutral → Buy $48 → $69
Apr-28-20Downgrade BofA/Merrill Buy → Neutral $46 → $51
Mar-18-20Downgrade JP Morgan Overweight → Neutral $23 → $33
Mar-09-20Initiated H.C. Wainwright Neutral $30
Jan-24-20Downgrade SVB Leerink Outperform → Mkt Perform
Jan-22-20Downgrade UBS Buy → Neutral $35
Nov-05-19Initiated Wolfe Research Outperform
Nov-04-19Initiated UBS Buy $21
Nov-04-19Initiated SVB Leerink Outperform
Nov-04-19Initiated JP Morgan Overweight $23
Nov-04-19Initiated Canaccord Genuity Buy $22
Nov-04-19Initiated BofA/Merrill Buy $21
Nov-04-19Initiated Berenberg Buy $25
Jul-14-20 08:27AM  
07:42AM  
Jul-13-20 04:46PM  
04:44PM  
04:29PM  
03:25PM  
02:30PM  
12:51PM  
12:03PM  
11:31AM  
09:44AM  
08:58AM  
07:48AM  
06:57AM  
06:45AM  
Jul-12-20 01:02PM  
06:12AM  
Jul-10-20 07:18PM  
02:34PM  
09:54AM  
09:32AM  
Jul-08-20 10:05AM  
Jul-07-20 06:45AM  
Jul-04-20 09:25AM  
Jul-02-20 12:34PM  
11:05AM  
09:32AM  
09:09AM  
08:42AM  
06:21AM  
Jul-01-20 11:41PM  
08:13PM  
06:07PM  
03:18PM  
02:36PM  
01:21PM  
11:54AM  
11:06AM  
10:52AM  
10:21AM  
10:18AM  
10:08AM  
09:36AM  
09:28AM  
09:25AM  
09:19AM  
09:01AM  
08:59AM  
Jun-30-20 09:19PM  
08:47AM  
Jun-29-20 02:06PM  
06:08AM  
03:00AM  
Jun-25-20 11:43AM  
09:53AM  
Jun-23-20 10:28AM  
Jun-18-20 06:18PM  
Jun-17-20 10:14AM  
Jun-16-20 01:18PM  
12:06PM  
Jun-15-20 12:18PM  
11:45AM  
11:37AM  
Jun-13-20 06:22AM  
Jun-12-20 12:31PM  
Jun-11-20 08:23AM  
03:00AM  
Jun-08-20 07:55AM  
Jun-07-20 07:02AM  
Jun-05-20 11:59AM  
Jun-03-20 03:07PM  
Jun-01-20 08:57AM  
07:47AM  
May-31-20 07:32AM  
May-29-20 09:59AM  
May-28-20 11:34AM  
May-26-20 10:52AM  
09:59AM  
May-22-20 07:29AM  
May-21-20 05:51PM  
May-20-20 08:11AM  
May-19-20 06:50PM  
11:39AM  
May-18-20 11:20AM  
May-15-20 07:16PM  
May-14-20 11:51AM  
08:13AM  
May-13-20 03:29AM  
01:00AM  
May-09-20 01:23PM  
May-06-20 04:15PM  
03:34PM  
02:15PM  
May-05-20 04:26PM  
04:13PM  
02:58PM  
02:01PM  
01:06PM  
11:10AM  
10:11AM  
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in developing FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/II trial for prostate cancer; BNT113, which is in Phase I trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116, which is in preclinical trail for non-small cell lung cancer. It also develops individualized neo-antigen specific immunotherapies, such as RO7198457, which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT152 for multiple solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT212 for pancreatic and other cancers; and next-generation checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II a clinical trial to treat multiple solid tumors. Further, it develops MVT-5873, an IgG1 monoclonal antibody, which is in Phase I/II clinical trial for pancreatic cancer; BNT411, small molecule immunomodulator product candidate for solid tumors; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc., Sanofi S.A., Genmab A/S, Genevant Sciences GmbH, Eli Lilly and Company, Bayer AG, Pfizer Inc., and Shanghai Fosun Pharmaceutical (Group) Co., Ltd. The company was founded in 2008 and is headquartered in Mainz, Germany.